Lives, and lets live
researchers have evolved a technology to manufacture vaccines that do not need to be refrigerated. The feat may enable additional vaccination of 10 million children every year, claim officials of the uk-based Cambridge Biostability, which will manufacture the vaccine in collaboration with Panacea Biotec, New Delhi. The vaccine will simultaneously work against diphtheria, tetanus, whopping cough, hepatitis b and a form of meningitis.
Worldwide, about two million children die every year from vaccine-preventable diseases; at the same time, up to half the vaccines get damaged because of temperature-induced changes.
The key to the new technique is encasing the active ingredients of a vaccine in a sugary coat, which preserves them even at a temperature of 60
Related Content
- How much does reducing inequality matter for global poverty?
- Danger in the air: how air pollution can affect brain development in young children
- Sidhwan success motivates them to live green
- WORLD CANCER DAY 2015:GLOBAL PRESS RELEASE
- AFFORDABILITY OF HEALTH CARE IS A SERIOUS PROBLEM FOR VAST MAJORITY OF POPULATION, ESPECIALLY IN TERTIARY CARE – VICE PRESIDENT
- Centre for Science and Environment International Workshop Series on Transport and Climate